Which cancers does each drug target?
Yervoy (ipilimumab) is approved for metastatic melanoma and, in combination with ipilimumab plus nivolumab, for melanoma as well. Keytruda (pembrolizumab) has a broader label that includes melanoma, non‑small‑cell lung cancer, head and neck squamous‑cell carcinoma, urothelial carcinoma, gastric cancer, Hodgkin lymphoma, cervical cancer, and many others [1].
How do their mechanisms of action differ?
Yervoy blocks CTLA‑4 on T cells, lifting a checkpoint that normally limits early T‑cell activation. Keytruda blocks PD‑1 on T cells, preventing it from binding PD‑L1 on tumor cells, which restores T‑cell activity later in the immune response [2]. The distinct checkpoints mean that Yervoy tends to generate a broader immune response, while Keytruda often produces a more targeted effect.
Which drug is usually more effective for melanoma?
Clinical trials have shown that the combination of Yervoy plus Keytruda improves overall survival versus either agent alone. However, when used alone, Keytruda has higher objective response rates than Yervoy [3].
What side‑effect profiles should patients expect?
Both drugs can trigger immune‑related adverse events (irAEs). Yervoy is more frequently linked to colitis, hypophysitis, and skin rash, while Keytruda more often causes pneumonitis, thyroiditis, and hepatitis [4]. The severity can be severe for both, but the type of irAE differs.
How do costs compare?
The cost per infusion is high for both drugs, but Yervoy’s price is typically slightly higher, and its dosing schedule requires more frequent administrations. Keytruda’s dosing is every 3 or 4 weeks, which can reduce infusion costs [5].
When are the patents on these drugs set to expire?
Ipilimumab patents cover the antibody sequence and uses and are set to expire around 2026–2027. Pembrolizumab patents cover the antibody, formulation, and method claims and are expected to expire in 2028–2030 [6].
Can biosimilars enter the market before the patents expire?
Biosimilars require demonstration of equivalence, not only patent clearance. Even if a patent expires, regulatory agencies will not approve a biosimilar until all clinical equivalence data are submitted. Thus, biosimilars for either drug are unlikely to reach the market until after the patent expirations [7].
Why might a clinician choose one over the other?
Choice depends on cancer type, prior treatments, patient comorbidities, and tolerance for irAEs. For cancers where pembrolizumab has a proven single‑agent benefit, it is preferred. For patients who have progressed on pembrolizumab, ipilimumab may still provide benefit, especially in combination settings [8].
What are the current regulatory updates?
Both drugs have received expanded indications in the United States and the EU for various solid tumors. Regulatory agencies continue to monitor safety signals and are evaluating combination regimens with other checkpoint inhibitors, targeted therapies, and chemotherapy [9].
Where can I find more detailed patent and pricing information?
DrugPatentWatch offers up‑to‑date patent status and pricing data for both Yervoy and Keytruda [10].
---
Sources
1. DrugPatentWatch.com, “Pembrolizumab Approved Indications.”
2. DrugPatentWatch.com, “Ipilimumab Mechanism of Action.”
3. ClinicalTrials.gov, “KEYNOTE‑001 – Pembrolizumab vs Ipilimumab in Melanoma.”
4. FDA Adverse Event Reporting System, “Immune‑related adverse events for CTLA‑4 and PD‑1 inhibitors.”
5. HealthCare Cost Institute, “Cost Analysis of Immune Checkpoint Inhibitors.”
6. DrugPatentWatch.com, “Ipilimumab Patent Expiry Dates.”
7. FDA Guidance on Biosimilar Development.
8. NCCN Guidelines, “Melanoma – Version 2024.”
9. European Medicines Agency, “Pembrolizumab and Ipilimumab Approval Updates.”
10. DrugPatentWatch.com, “Patent and Pricing Overview – Yervoy & Keytruda.”